Form 4: Amgen VP, Finance & CAO Matthew C. Busch Reports Changes in Beneficial Ownership

Matthew C. Busch, VP, Finance & CAO of Amgen Inc., reports a transaction involving common stock due to tax withholding upon vesting of Restricted Stock Units.

Summary

• On November 5, 2024, Matthew C. Busch, VP, Finance & CAO of Amgen Inc., filed a Form 4 indicating changes in beneficial ownership of Amgen's common stock.
• The transaction involved the disposition of 189 shares at a price of $316.91 per share.
• This disposition was related to tax withholding upon the vesting of Restricted Stock Units (RSUs).
• Following the transaction, Busch beneficially owns 4,770 shares of Amgen common stock.
• These shares include various RSUs with vesting dates ranging from April 30, 2025, to May 7, 2028.
• The shares also include 90 Dividend Equivalents (DEs) granted pursuant to the Company's Equity Plan and subject to a qualifying dividend reinvestment plan.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to stock transactions by a company executive. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies like Amgen. It provides transparency regarding the holdings and transactions of company insiders.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it is a routine stock transaction by an executive.

Key Dates